Literature DB >> 23910648

Targeted case finding for hepatitis B using dry blood spot testing in the British-Chinese and South Asian populations of the North-East of England.

S McPherson1, M Valappil, S E Moses, G Eltringham, C Miller, K Baxter, A Chan, K Shafiq, A Saeed, R Qureshi, M Hudson, M F Bassendine.   

Abstract

Chronic infection with the hepatitis B virus (HBV) is a frequent cause of cirrhosis and liver cancer. Targeted HBV screening is recommended by the Centre for Disease Control (CDC) and Prevention for subjects born in countries with >2% HBV prevalence. However, there are no UK guidelines. Here, we applied the (CDC) recommendations to the British-Chinese and British-South Asian community of North-East (NE) England. British-Chinese and South Asian subjects were invited to attend for HBV education and screening sessions held in community centres. Hepatitis B surface antigen (HBsAg) and hepatitis B core total antibody (HBcAb) were tested with dry blood spot tests. South Asians were also tested for hepatitis C antibody (HCVAb). A total of 1126 subjects (606 Chinese and 520 South Asian) were screened. Sixty-two (5.5%) were HBsAg positive. Ten of these reported a previous diagnosis of HBV. The prevalence of HBsAg positivity was 4.6% when previously diagnosed individuals were excluded. The HBsAg prevalence was significantly higher in the Chinese subjects compared with South Asians (8.7% VS. 1.7% P < 0.001). In Chinese subjects, HBsAg positivity was highest in subjects born in Vietnam (17.4%), followed by China (11%), Hong Kong (7.8%) and the UK (6.7%). Subjects from Pakistan had the highest HBsAg and HCV Ab prevalence in the South Asians (3.1% and 1.8%, respectively). Ten percentage of HBsAg positive patients who had follow-up assessment had active disease requiring antiviral treatment. Undiagnosed HBV infection was above the 2% threshold for screening suggested by the CDC in the British-Chinese and Pakistani community of NE England, which provides evidence for a UK HBV-targeted screening programme.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  case finding; dry blood spot testing; hepatitis B; hepatitis C; screening

Mesh:

Substances:

Year:  2013        PMID: 23910648     DOI: 10.1111/jvh.12084

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  16 in total

1.  A prospective clinical trial to compare the performance of dried blood spots prenatal screening for Down's syndrome with conventional non-invasive testing technology.

Authors:  Huiying Hu; Yulin Jiang; Minghui Zhang; Shanying Liu; Na Hao; Jing Zhou; Juntao Liu; Xiaojin Zhang; Liangkun Ma
Journal:  Exp Biol Med (Maywood)       Date:  2017-01-05

Review 2.  Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.

Authors:  Claus Niederau
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

3.  Hepatitis B in pregnancy.

Authors:  Jessica Katharine Dyson; Julia Waller; Andrena Turley; Enid Michael; Samuel Moses; Manoj Valappil; Mark Hudson; Margaret Bassendine; Stuart McPherson
Journal:  Frontline Gastroenterol       Date:  2013-10-17

4.  Exploring the acceptability of a 'limited patient consent procedure' for a proposed blood-borne virus screening programme: a Delphi consensus building technique.

Authors:  Denise Crane; Emily J Henderson; David R Chadwick
Journal:  BMJ Open       Date:  2017-05-29       Impact factor: 2.692

5.  Estimating the scale of chronic hepatitis B virus infection among migrants in EU/EEA countries.

Authors:  Amena A Ahmad; Abby M Falla; Erika Duffell; Teymur Noori; Angela Bechini; Ralf Reintjes; Irene K Veldhuijzen
Journal:  BMC Infect Dis       Date:  2018-01-11       Impact factor: 3.090

Review 6.  Improving access to health care for chronic hepatitis B among migrant Chinese populations: A systematic mixed methods review of barriers and enablers.

Authors:  A Vedio; E Z H Liu; A C K Lee; S Salway
Journal:  J Viral Hepat       Date:  2017-02-20       Impact factor: 3.728

7.  Low hepatitis B testing among migrants: a cross-sectional study in a UK city.

Authors:  Iro Evlampidou; Matthew Hickman; Charles Irish; Nick Young; Isabel Oliver; Sophie Gillett; Alexandra Cochrane
Journal:  Br J Gen Pract       Date:  2016-03-29       Impact factor: 5.386

8.  Improving testing for hepatitis B before treatment with rituximab.

Authors:  Jessica K Dyson; Laura Jopson; Sarah Ng; Matthew Lowery; Jayne Harwood; Sheila Waugh; Manoj Valappil; Stuart McPherson
Journal:  Eur J Gastroenterol Hepatol       Date:  2016-10       Impact factor: 2.566

9.  Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries.

Authors:  A M Falla; A A Ahmad; E Duffell; T Noori; I K Veldhuijzen
Journal:  BMC Infect Dis       Date:  2018-01-16       Impact factor: 3.090

10.  Limited access to hepatitis B/C treatment among vulnerable risk populations: an expert survey in six European countries.

Authors:  Abby M Falla; Irene K Veldhuijzen; Amena A Ahmad; Miriam Levi; Jan Hendrik Richardus
Journal:  Eur J Public Health       Date:  2017-04-01       Impact factor: 3.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.